Key Takeaways
- 20% top-line growth, mix pressure on margins: Revenue grew 20% YoY, but gross margin fell ~230 bps to 60.6% as the lower-margin Sanofi portfolio and higher ARV sales shifted the mix; base business gross margins were stable.
- Lenacapavir in-licensed, but years from revenue: The Gilead deal adds a "path-breaking" ARV asset with prophylactic upside, yet the development cycle alone is 18–24 months, and management has no commercial sizing yet.
- Derma gets a dedicated subsidiary and CEO: Emcutix was formed as a 100% subsidiary, a new team onboarded, and a Galderma veteran appointed CEO; no targets were given, but launches are promised.
- Operating leverage is the margin story for 2H: EBITDA margin improved 50 bps QoQ ex one-time items; management expects better 2H margins from factory operating leverage, rising MR productivity, and a back-ended non-ARV EM business.
- What to watch next quarter: Whether the acute-market slowdown persists, any quantification of Lenacapavir’s commercial path, and the pace of gross-margin recovery as the Sanofi/ARV mix effect plays through.
Domestic Business: Sanofi Integration Offsets Acute Weakness
- Sanofi portfolio carried the quarter: Domestic revenue grew 15% YoY; ex-Sanofi and ex-FCM, the base business grew 7–8%, with volume contributing 3–4%, price 2–3%, and new products 2–3%.
- FCM drag still material: The product went off patent in October last year, so the year-ago comparator still includes its contribution, making reported growth look weaker.
- Acute market slowed unexpectedly: The monsoon-driven pickup did not materialize; management cited competing theories (generics, Jan Aushadhi, new government stores) but called the cause "very difficult to hazard a guess."
- Field force split at Zuventus: 50% of net headcount additions went to Zuventus, where one large division was vertically split across geographies to give mega-brands more detailing attention.
- Therapy focus for the next 2–3 years: Gynaec, Cardio (with Sanofi integration now fully behind), Diabetes, Derma, CNS (led by Tenecteplase), and anti-infectives/vitamins via the Zuventus field force.
Satish Mehta: "Gagan, it's very difficult to hazard a guess. There are lots of theories which are being flouted around. Somebody says that generic business is taking their share, Jan Aushadhi is playing, and even for that matter, the new stores, so that the government of India is very actively starting. So, it's very difficult to come to any conclusion. Maybe it will take some time before we know what's happening."
International: ARV Recovery and Canada Outperformance
- International grew 25% YoY, led by emerging markets and Canada; EU growth was healthy at 7% in H1 but is expected to be muted for the full year.
- ARV business rebounding: After two muted years, the order book is "fairly strong" with good visibility for FY25, helped by new launches from the Kadu facility in the PEPFAR segment; roughly half of rest-of-world revenue was ARV this quarter.
- Non-ARV traction building: Differentiated products are gaining ground; the stroke product (Tenecteplase) is well received in India and emerging markets, with registrations secured in Sri Lanka and the Philippines imminent.
- Canada boosted by Mantra and competitor disruption: Mantra is tracking slightly above internal expectations for H1, partially benefiting from supply disruptions at peers with regulatory issues; profitability is broadly in line with or slightly above the overall company EBITDA margin.
- Mantra synergies still unfolding: Opportunities to take products across Canada and existing Canadian products into Quebec will continue to play out over the next 12 months.
Lenacapavir: A Long-Dated ARV Option with Prophylactic Upside
- In-licensed from Gilead for India and emerging markets, Lenacapavir is described as a "path-breaking product in the ARV treatment regime."
- Development timeline is 18–24 months from tech-pack receipt to filing, then regulatory approvals and commercialization; domestic India approval and launch could come earlier, while other markets will be more elongated.
- Prophylactic indication could transform the market: Trials are underway for preventive use; if successful, the market size itself could expand beyond the current treatment-only ARV market, making the product's potential "far larger than the current ARV market."
- No commercial sizing yet: Management declined to give a concise assessment of the molecule's potential at commercial launch, leaving the revenue path unquantified.
Samit Mehta: "I believe the potential of this product could possibly be far larger than the current ARV market. The reason being is, while today it is approved only as a treatment, I understand that trials are also going on for use of this molecule in a preventive or prophylactic indication. So, if that comes through, probably the market size itself will increase compared to where it is today."
Margins: Mix Pressure Now, Operating Leverage Later
- Gross margin fell to 60.6% from 62.9% YoY, driven entirely by business mix: the Sanofi portfolio carries lower margins and ARV sales were higher; base business gross contribution percentages were stable year-on-year.
- EBITDA margin at 20.8% was higher than both Q2 FY24 and Q1 FY25, partly aided by other income; excluding one-time other income, base margins improved ~50 bps QoQ from operating leverage and MR productivity gains.
- Depreciation jumped to ₹97 crores from ₹70 crores YoY due to the Mantra acquisition and operationalization of four new plants; QoQ it was largely stable.
- Interest cost included a one-time ₹8 crore loan prepayment charge; going forward, interest will be lower due to debt reduction, with management guiding a ~₹25 crore reduction in the second half.
- 2H margin drivers: Factory-side operating leverage, rising MR productivity, and a back-ended non-ARV emerging markets business that should pull margins up as it scales in the second half.
- PCPM trajectory improving: Q2 at 6.6 vs. 6.3 in Q1 and 5.9 in Q2 last year; aspiration is to reach the high 6s by FY25 end.
Strategic Moves: Derma Subsidiary, Biosimilars Facility, and In-Licensing
- Emcutix, a new 100% Derma subsidiary, was set up with a freshly onboarded team; Sathya Narayanan, previously CEO & MD of Galderma South Asia, was appointed CEO. Management promised new product launches and initiatives but declined to give any revenue or timeline targets.
- EU GMP approval for the biologics facility was received, which will accelerate approvals in targeted emerging markets; the facility will now be used for validation batches and product filings.
- In-licensing remains a core domestic growth lever, spearheaded by the MD; the company will continue looking for opportunities to build the domestic business, with India as a key focus market for brand acquisitions going forward.
- Etodolac + Paracetamol discontinued after being placed on the irrational FDC list; contribution was less than ₹10 crores.
Satish Mehta: "I am happy to announce that we have recently onboarded a new team in our Derma to grow that business. To give adequate focus to Derma, we have set up a new 100% owned subsidiary, Emcutix to grow that business."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue growth | 20%+; on track to deliver | FY25 |
| 2H margin improvement | 2H margins better than 1H; endeavour to improve | FY25 2H |
| Interest cost reduction | Come down by ~₹25 crores in second half | FY25 2H |
| PCPM target | Reach high 6s territory | FY25 end |
| Lenacapavir development cycle | 18–24 months from tech pack to filing | From tech-pack receipt |
| Organic international growth | Low double digits, given geographic mix | Ongoing |
| Domestic growth aspiration | Slightly faster than overall industry (high single digits) | Ongoing |
| Europe growth target | Double-digit growth | Going forward |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue from operations | ₹2,002 cr, +20% YoY |
| Domestic revenue | ₹933 cr, +15% YoY |
| Domestic revenue ex-FCM and ex-Sanofi | +7–8% YoY and +3% QoQ |
| International revenue | ₹1,069 cr, +25% YoY; organic growth +14% |
| Canada revenue | ₹296 cr, +51% YoY |
| Europe revenue | ₹362 cr, +6% YoY |
| Emerging markets revenue | ₹411 cr, +29% YoY |
| Gross margin | 60.6%, vs 62.9% in Q2 FY24 |
| EBITDA | ₹417 cr, +26% YoY |
| EBITDA margin | 20.8%, higher than Q2 FY24 and Q1 FY25 |
| Base margin ex one-time other income | +50 bps QoQ |
| PAT | ₹202 cr, +38% YoY |
| Depreciation and amortization | ₹97 cr, vs ₹70 cr YoY |
| Interest cost | ₹46 cr, includes ₹8 cr one-time prepayment expense |
| Estimated tax rate | ~26% |
| Net debt | ₹705 cr, down from ₹1,558 cr at start of fiscal year and ₹846 cr at end July |
| Working capital days | ~96 days at end September |
| Full-year revenue growth guidance | 20% plus |
| Full-year EBITDA margin guidance | 20% to 21% |
| PCPM (per contact per month) | ~6.6, vs 6.3 in Q1 FY25 and 5.9 in Q2 FY24 |
| Domestic volume growth ex-Sanofi, ex-FCM | 3–4% |
| Domestic pricing growth ex-Sanofi, ex-FCM | 2–3% |
| Domestic new products contribution ex-Sanofi, ex-FCM | 2–3% |
| H1 Europe growth | 7% |
| Organic overall growth | ~12% |
| Interest cost reduction expected in H2 | ~₹25 cr |
| Forex gains in other income | ~₹5 cr |
| Discontinued product (Etodolac + Paracetamol) contribution | less than ₹10 cr |
| Mehsana oral solids facility utilization | closer to 50% |